Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Randomized Double-blind Placebo Controlled Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention

NCT03238781 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT03238781
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03238781 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Randomized Double-blind Placebo Controlled Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
September 6, 2017
Completion date
February 4, 2019
Enrollment
343 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

chronic migraine or episodic migraine